Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyPediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.Histone deacetylase inhibitors in Hodgkin lymphoma.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunctionThe histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Regulation of immune responses by histone deacetylase inhibitorsThe pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.Trial watch: Chemotherapy with immunogenic cell death inducersCCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironmentRelapsed Hodgkin lymphoma: management strategiesMocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells.Emerging drugs for Hodgkin's lymphoma.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
P2860
Q26745842-17EDE958-FABF-40A6-86A9-DDA72C3FEB7FQ26797280-D433A717-D3E4-41D2-B655-2E94C6AB29A7Q27002554-9564E0DA-782C-4E4F-9971-B58163B1F61DQ28082536-27DF23A3-10EA-4919-B4AE-B62E1D0104FAQ30248284-21CE9C1C-4301-43C8-B8E0-BA7556F89330Q30251920-0A6E8137-9213-40AE-AA8E-4B9459F49373Q33392081-633D5E57-67E6-4D5D-9FF1-FD3D3DFC648AQ33410761-234C85B6-175F-47C5-BFEE-0FD449568955Q33432027-2C36E641-0FAC-4427-B6E5-8F544B87D154Q33711558-DB44203C-BAF5-4A3F-A534-2EFA97D8CEB1Q34414440-77525E2F-3525-49E1-B1F5-B2B062305C03Q34414452-4C080326-26FB-43FD-B201-1D96ACB8678EQ34557179-3E9872B8-3301-45E0-87DC-0531E636D204Q34640790-844C72D4-6A2A-45AE-B166-AF5D586DB07EQ34648812-F78E5B52-2A6F-44B7-B8B3-0D9CC6D17D2CQ34672100-72A5B56B-0FFD-458B-AB29-984D19EC8026Q34707183-41123040-B6CB-4C66-8632-3C43A89D2273Q35018530-46EC4FDC-0624-4BC6-8290-603B60611758Q35053177-153822C9-7C70-4394-B303-15E311D6C40AQ35061825-0FF72EBF-F0E0-4C67-929F-8C28985FD6C5Q35223868-CCDF9BCD-6A06-4EA4-BB1C-F27E856BE7FDQ35235267-70E047BF-1D6C-4959-9765-70A0EA1AF01EQ35664956-3190E041-C994-42A9-90CA-60ACC313DD04Q35741591-0E5800ED-0BD3-4580-93DC-00DD11BEB6F9Q35855571-71FD451B-AD5A-4FFF-AAB9-195CC4F04944Q35953399-D01104F9-79A0-4C66-947D-684CAFEFC945Q36038456-1ECA06F1-2430-452F-879D-F4C972FE6D08Q36288217-B111DF76-2956-4ADE-8084-8982F9FB86A6Q36309396-CB3BB7FF-B1D4-4022-B7A0-00AD8C03256AQ36337623-D8691411-F658-48FE-9702-BAFDF13AB6B4Q36660672-A9F1E606-2E02-48CC-973B-EBBA1A9E858AQ36922528-37BA6304-7348-40F0-AAAC-49DE56D079C3Q37008427-4481F3AB-B957-404B-BC8A-5521F6E50529Q37296330-F0AC9C50-668C-4EFF-8CA2-E99E08696582Q37417291-1FFB48D5-583F-4038-A051-674A44C981D3Q37421431-D3255B0C-07FE-4310-AEB9-3F6F8B122AA3Q37641580-EA88800B-BEE8-4A72-9996-BA81EAC9DB1EQ37772513-389FF111-4838-4219-AA13-72E2F10D93E5Q37774667-8E7C090A-745C-4526-8CEC-F88D0720764EQ37786716-6EDFA7F1-DAF5-4F01-BF15-FC4CA6849A66
P2860
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines
@en
Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.
@nl
type
label
Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines
@en
Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.
@nl
prefLabel
Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines
@en
Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.
@nl
P2093
P2860
P1433
P1476
Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines
@en
P2093
Anas Younes
Daniela Buglio
Georgios V Georgakis
Noor M Khaskhely
Shino Hanabuchi
Yong-Jun Liu
P2860
P304
P356
10.1182/BLOOD-2008-01-133769
P407
P577
2008-06-09T00:00:00Z